Is Vericel (VCEL) overvalued or fairly valued?

MarketChacha shows Vericel's valuation in context — a trailing P/E of about 4012.0, a forward P/E of about 47.4, a price-to-book of about 5.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Vericel's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (6.13×) from reported figures — education, not a rating.

What is Vericel's revenue?

Vericel reported revenue of $276.3M for FY2025, with net profit of $16.5M, per official filings.

What is the share price of Vericel (VCEL)?

Vericel last traded at $40.12 (-0.6% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Vericel

VCEL · NYSE · Healthcare · United States

Snapshot

TickerVCEL

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees398

HeadquartersBurlington, United States

Websitewww.vcel.com

Filings tracked13

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

Who owns it

Insiders1.2%
Institutions98.8%
Public & other0.0%

430 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.15.80%
State Street Corporation6.43%
Congress Asset Management Co4.98%
Vanguard Capital Management LLC4.41%
Conestoga Capital Advisors, LLC4.07%
William Blair Investment Management, LLC3.89%
BNP Paribas Asset Management Holding S.A.3.20%
GW&K Investment Management, LLC3.03%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 4.7% is on the low side — the business earns a modest return on shareholder capital.

Cash conversion6.13×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend-1.6% → 6.0%

Margin has expanded by about 7.6 points — the business is getting more profitable.

Return on equity4.7%

Latest ROE of 4.7% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $112.4M · EPS 0.53

Est. earnings growth +18.7%

Next fiscal year

Rev $392.9M · EPS 0.85

Est. earnings growth +63.9%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$276.3M

Net margin

6.0%

ROE

4.7%

Revenue CAGR (2y)

+18.3%

EPS (FY2025)

0.32

Net profit (FY2025)

$16.5M

Ask MarketChacha about VCEL

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$276.3M	$16.5M	0.32	6.0%	4.7%
FY2024	$237.2M	$10.4M	0.20	4.4%	3.5%
FY2023	$197.5M	$-3.2M	-0.07	-1.6%	-1.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$77.5M	$2.2M	0.04	2.8%
2026Q1	$68.4M	$-6.3M	-0.12	-9.2%
2025Q3	$67.5M	$5.1M	0.10	7.5%
2025Q2	$63.2M	$-553,000	-0.01	-0.9%
2025Q1	$52.6M	$-11.2M	-0.23	-21.4%
2024Q3	$57.9M	$-901,000	-0.02	-1.6%
2024Q2	$52.7M	$-4.7M	-0.10	-8.9%
2024Q1	$51.3M	$-3.9M	-0.08	-7.5%
2023Q3	$45.6M	$-3.7M	-0.08	-8.0%
2023Q2	$45.9M	$-5.0M	-0.11	-10.9%
2023Q1	$41.0M	$-7.5M	-0.16	-18.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC7/30/2026material
10-Q filing
SEC7/30/2026
8-K — Bylaw/charter change, Exhibits
SEC5/18/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Shareholder vote results, Exhibits
SEC5/1/2026material
8-K — Results of operations, Exhibits
SEC2/26/2026material
10-K filing
SEC2/26/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/13/2026material

2025

8-K — Results of operations, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Results of operations, Exhibits
SEC7/31/2025material
10-Q filing
SEC7/31/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.